Proto Script Pharmaceutical Corp (PSCR) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Proto Script Pharmaceutical Corp $0.00, price $0.00, upside +0.0%, quality 30 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Proto Script Pharmaceutical Corp. engages in the repair and rental of power wheelchairs and scooters. The company serves federal, state, and private insurance providers. Proto Script Pharmaceutical Corp. was founded in 2001 and is headquartered in Rancho Cucamonga, California.
Stock analysis
Proto Script Pharmaceutical Corp (PSCR) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, so the stock looks roughly fairly valued today (gap 0.0%).
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 80/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Industrials sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
Proto Script Pharmaceutical Corp reported revenue of $0 in FY2016 versus $948K in FY2014. Reported net income was −$33.1K in FY2016.
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 67% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 1% fair-value upside, at 0%, PSCR screens richer than that median.
Fair Value models
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2016 is a loss year, no rate is defined from a loss
Compare Proto Script Pharmaceutical Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Business Services · 234 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score30 · Bottom 25%
Fair Value upside+0.0% · Below median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Operating margin (TTM)−33.9% · Bottom 25%
Growth and dividend
Revenue growth17.8% · Top 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Specialty Business Services median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/FCF0.2× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)33· sector 43
FUTURE (revenue growth)89· sector 31
PAST (return on equity)0· sector 37
HEALTH (low debt)0· sector 93
DIVIDEND (yield)0· sector 53
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Proto Script Pharmaceutical Corp (PSCR) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% upside (fairly valued).
What is the fair value of PSCR?
Our model-based fair value for Proto Script Pharmaceutical Corp is $0.0001 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.0001.
What is the quality score of PSCR?
Proto Script Pharmaceutical Corp has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Proto Script Pharmaceutical Corp (PSCR)?
Our model-based price target is the fair value of $0.0001 (as of Oct 3, 2026) from 2 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Proto Script Pharmaceutical Corp stock forecast for 2026?
Our models put fair value at $0.0001, about +0% upside versus a price of $0.0001 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Proto Script Pharmaceutical Corp (PSCR)?
Proto Script Pharmaceutical Corp reported trailing-twelve-month revenue of about $605K (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Proto Script Pharmaceutical Corp (PSCR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Proto Script Pharmaceutical Corp it is $0.0001 per share (as of Oct 3, 2026), against a price of $0.0001. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Proto Script Pharmaceutical Corp stock overvalued or undervalued in 2026?
As of Oct 3, 2026, PSCR trades below its calculated fair value: price $0.0001, fair value $0.0001, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PSCR?
No. The price is what the market pays today ($0.0001); the fair value is what the company's own numbers justify ($0.0001). For Proto Script Pharmaceutical Corp the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Proto Script Pharmaceutical Corp worth?
The market values Proto Script Pharmaceutical Corp at about $4.9K (market capitalisation, as of Oct 3, 2026). Per share that is $0.0001; our models calculate a fair value of $0.0001 per share.
How solid is the balance sheet of Proto Script Pharmaceutical Corp (PSCR)?
Balance-sheet figures for Proto Script Pharmaceutical Corp (as of Oct 3, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is PSCR from its 52-week high?
Proto Script Pharmaceutical Corp trades at $0.0001, about 67% below its 52-week high of $0.0003 and at the low of $0.0001 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0001 is for.
Which stocks are comparable to Proto Script Pharmaceutical Corp?
From the same area (Industrials) we also value Cintas Corporation, Thomson Reuters Corporation, Copart, Inc, Global Payments Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Proto Script Pharmaceutical Corp stock attractive at the current price?
The data as of Oct 3, 2026: price $0.0001, calculated fair value $0.0001 (+0%), Quality Score 30/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PSCR calculated?
We run Proto Script Pharmaceutical Corp through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0001, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Proto Script Pharmaceutical Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Proto Script Pharmaceutical Corp (PSCR)?
The closing price on Oct 2, 2026 was $0.0001. Our model-based fair value is $0.0001, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Proto Script Pharmaceutical Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Proto Script Pharmaceutical Corp
How large is the market capitalisation of Proto Script Pharmaceutical Corp (PSCR)?
The market capitalisation of Proto Script Pharmaceutical Corp is $4.9K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the EBIT return on assets of Proto Script Pharmaceutical Corp (PSCR)?
On an EBIT basis the return on assets of Proto Script Pharmaceutical Corp is −2,560% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Proto Script Pharmaceutical Corp (PSCR)?
The operating margin of Proto Script Pharmaceutical Corp is −33.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Proto Script Pharmaceutical Corp (PSCR)?
Revenue at Proto Script Pharmaceutical Corp is growing +17.8% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Proto Script Pharmaceutical Corp (PSCR) generate?
The free cash flow of Proto Script Pharmaceutical Corp is $28.9K (fiscal year 2016). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Proto Script Pharmaceutical Corp (PSCR) carry?
The net debt of Proto Script Pharmaceutical Corp is $47.8K (fiscal year 2016, ≈ 1.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Proto Script Pharmaceutical Corp in the live analysis
One click puts Proto Script Pharmaceutical Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Oct 3, 2026